Clinical trials: α-synucleinopathy, open to volunteers
Parkinson Disease (PD)
Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution
Parkinson's disease (PD) presents a complex challenge due to its progressive neurodegenerative nature, affecting various bodily systems.
- Trial name
- VaMPiRE (NCT06941012)
- Testing
- Blood draw for the laboratory assessment
- Where
- 4 sites in Greece, Italy and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Casa di Cura IGEA
α-synucleinopathy
A Registered Cohort Study on α-Synucleinopathy
α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. The data to be collected is intended to help healthcare providers make important medical decisions concerning α-synucleinopathy…
- Trial name
- NCT05527067
- Testing
- Data collection
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Parkinson's Disease
Prevent Cognitive Decline in GBA-associated Parkinson's Disease
This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene.
- Trial name
- PreCoDe (NCT07055087)
- Testing
- Prasinezumab, Sodium Chloride
- Where
- 11 sites in France, Germany and 5 more
- Volunteers
- 120 people
- Sponsor
- University Hospital Tuebingen
Parkinson´s Disease, REM Sleep Behavior Disorder (iRBD)
The Swedish BioFINDER Sleep Study
BioFINDER-Sleep study was established in 2021 and will include patients with early Parkinson´s disease (PD) and persons with iRBD to provide essential insights into the underlying mechanisms of the progressive neurodegenerative…
- Conditions
- Parkinson´s Disease, REM Sleep Behavior Disorder (iRBD), Lewy Body Disease, Synucleinopathy
- Trial name
- NCT07533799
- Testing
- Dopamine transporter PET scan with [18F]FE-PE2I, Magnetic resonance imaging (MRI), [123I] MIBG scintigraphy of the heart
- Where
- Sweden
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Parkinson Disease (PD)
Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease
Parkinson's disease (PD) poses a severe threat to human health, and its incidence is rising year by year. Current therapeutic options are limited by significant shortcomings.
- Trial name
- NCT07157345
- Testing
- PDR001
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Ruijin Hospital
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Multiple System Atrophy
A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia.
- Trial name
- NCT07774585
- Testing
- α-Syn H21 Monoclonal Antibody
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Ruijin Hospital
Parkinsons Disease (PD), Healthy Elderly Volunteers
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
This is a single-center, open-label clinical study designed to evaluate alpha-synuclein (ASYN) deposition in the brain of participants with Parkinson's disease (PD), as compared with healthy elderly (HE) participants.
- Trial name
- NCT07880379
- Testing
- [¹⁸F]MK-0947
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XingImaging, LLC
Alpha Synuclein Pathology, Alpha-Synuclein
Alpha-Synuclein PET/CT in Various α-Syn-Related Disease
To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.
- Conditions
- Alpha Synuclein Pathology, Alpha-Synuclein, Parkinson Disease
- Trial name
- NCT06949670
- Testing
- 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University